insights_auto
Kwa nini TRVN imepungua kwa 99.24%?
Fahamu zaidichevron_right
TRVN:OTCMKTS
Trevena Inc
US$Â 0.00050
arrow_downward
-99.24%(-0.066) Siku 1
16 Okt, 11:36:00 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya TRVN...
Fungua
US$Â 0.00
Juu
US$Â 0.00
Chini
US$Â 0.00
Mtaji wa soko
407.21
Wastani wa kiasi cha mauzo
210.00
Kiasi cha mauzo ya hisa
elfu 4.04
Juu kwa wiki 52
US$Â 1.50
Chini kwa wiki 52
US$Â 0.00
Beta
1.07
Hisa za wawekezaji
elfu 864.00
Idadi ya wafanyakazi
23
Fungua
US$Â 0.00
Juu
US$Â 0.00
Chini
US$Â 0.00
Mtaji wa soko
407.21
Wastani wa kiasi cha mauzo
210.00
Kiasi cha mauzo ya hisa
elfu 4.04
Juu kwa wiki 52
US$Â 1.50
Chini kwa wiki 52
US$Â 0.00
Beta
1.07
Hisa za wawekezaji
elfu 864.00
Idadi ya wafanyakazi
23
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
www.pei-privaterealestate.com
·
dakika 13 zilizopita
NASDAQ report tracks insurer shift toward real estate debt strategies in 2025
Investing News Network
·
saa 1 iliyopita
BCRF Launches $100 Million Venture Program for Breast Cancer: NYSE Content Update
Forbes
·
dakika 11 zilizopita
SK Hynix Opened Nasdaq. Will Seoul Keep It Open?
Yahoo Finance
·
dakika 25 zilizopita
Nasdaq Reports Network Disruption Affecting US Equities Data Feeds
Wasifu
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Kuhusu Trevena Inc
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazi23
Lilianzishwa2007
Makao makuuAtlanta, Georgia, Marekani
Sekta-
Tovutitrevena.com